News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Ariad Pharmaceuticals, Inc. to Receive $2.5 Million from Partner Merck & Co., Inc.
August 6, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CAMBRIDGE, Mass. (AP) -- Ariad Pharmaceuticals Inc. said Wednesday it will receive a $2.5 million payment from partner Merck & Co. for moving a cancer drug into midstage clinical trials.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Merck & Co.
MORE ON THIS TOPIC
Earnings
Gilead’s PrEP Launch Full Speed Ahead Despite Macro Pressures on HIV Space
April 25, 2025
·
3 min read
·
Tristan Manalac
Earnings
BMS Reports Mixed Earnings as Growth Portfolio Makes Up for Generic Pressure
April 24, 2025
·
2 min read
·
Dan Samorodnitsky
Earnings
Tariff Uncertainty Reigns Over Q1 Earnings, With Merck Taking $200M Blow So Far
April 24, 2025
·
3 min read
·
Annalee Armstrong
Startups
Novartis-, Sanofi-Backed Granite Brings $100M to Compete in Crowded I&I Space
April 24, 2025
·
2 min read
·
Tristan Manalac
